Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Supernus Pharmaceuticals, Inc.
SUPN
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.8B
$47.28
▼ -0.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$31.35 - $59.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 47.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established commercial portfolio with FDA-approved products generating consistent revenue
- Specialized expertise in CNS drug formulation, particularly extended-release technologies
- Late-stage pipeline addressing significant unmet medical needs in neurology and psychiatry
- Strategic focus on specialty pharmaceutical distribution channels with high barriers to entry
- Diversified product portfolio reducing reliance on single therapeutic indication
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Turning profitable
Steady revenue growth (9% YoY)
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Weak
-6.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SUPN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of $0.59 vs $0.28 consensus (+110.7% surprise). Revenue of $207.7M vs $192.9M expected (+7.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+110.7%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+6%
+4%
-2%
+9%
+21%
+39%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$168.3M
$175.7M
$174.2M
$149.8M
$165.5M
$192.1M
$211.6M
$207.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.